Mustafa Ozkaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mustafa Ozkaya has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Mehmet Demirel
Istanbul Faculty of Medicine, Department of Orthopaedics and Traumatology, Istanbul University, Istanbul, Turkey
2 shared publications - Taha Kizilkurt
Istanbul University, Turkey (Türkiye)
2 shared publications Berk Nimetoglu
Department of Orthopaedics and Traumatology, Faculty of Medicine, Istanbul University, Capa/Fatih, 34093 Istanbul, Türkiye
1 shared publicationCengiz Sen
Department of Orthopaedics and Traumatology, Faculty of Medicine, Istanbul University, Capa/Fatih, 34093 Istanbul, Türkiye
1 shared publicationHalil Ibrahim Balci
Department of Orthopaedics and Traumatology, Faculty of Medicine, Istanbul University, Capa/Fatih, 34093 Istanbul, Türkiye
1 shared publicationLevent Eralp
Complex Extremity Reconstruction Unit, Acibadem Hospital Group, Istanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 3 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4713
The Effect of Preoperative Intravenous Iron Supplementation on Mortality and Blood Transfusion Requirements in Elderly Patients Undergoing Hip Fracture Surgery: A Prospective Randomized Controlled Trial
Background/Objectives: Elderly patients who suffer a hip fracture often have a high risk of complications and mortality, which can be made worse by anemia during and after surgery. Although restrictive transfusion strategies are recommended, the role of preoperative intravenous iron, particularly ferric carboxymaltose (FCM), remains unclear. This study aimed to investigate whether preoperative IV FCM reduces mortality and transfusion requirements in geriatric hip fracture patients managed under a restrictive transfusion strategy. Methods: A study was conducted in which 220 patients aged 65 years and over who had undergone surgery for a hip fracture were included. These patients were allocated to receive either a single 1000 mg dose of intravenous FCM approximately 12 h before surgery or no iron supplementation. All the patients were managed with a standardized restrictive transfusion strategy. The primary outcome was all-cause mortality at 6 and 12 months. The secondary outcomes included perioperative transfusion requirement, hemoglobin trends, and length of hospital stay. Results: The FCM group demonstrated significantly lower mortality at both 6 months (22.9% vs. 39.0%, p = 0.011) and 12 months (28.4% vs. 42.9%, p = 0.028) compared to the control group. Multivariate logistic regression identified preoperative FCM administration as one of the independent protective factors for mortality. The FCM group had significantly lower transfusion rates (30.9% vs. 45.5%, p = 0.02). No significant difference was observed at the 6-week follow-up in terms of the higher discharge hemoglobin levels seen in the control group. The difference in hospital stay duration did not reach statistical significance. Conclusions: Preoperative intravenous FCM administration could reduce both short- and long-term mortality and transfusion needs in geriatric hip fracture patients managed under a restrictive transfusion protocol. These findings support further investigation of high dose IV iron as a component of perioperative blood management in this high-risk population.
- 3 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (13) , 4713
Open AccessThe Effect of Preoperative Intravenous Iron Supplementation on Mortality and Blood Transfusion Requirements in Elderly Patients Undergoing Hip Fracture Surgery: A Prospective Randomized Controlled Trial
Background/Objectives: Elderly patients who suffer a hip fracture often have a high risk of complications and mortality, which can be made worse by anemia during and after surgery. Although restrictive transfusion strategies are recommended, the role of preoperative intravenous iron, particularly ferric carboxymaltose (FCM), remains unclear. This study aimed to investigate whether preoperative IV FCM reduces mortality and transfusion requirements in geriatric hip fracture patients managed under a restrictive transfusion strategy. Methods: A study was conducted in which 220 patients aged 65 years and over who had undergone surgery for a hip fracture were included. These patients were allocated to receive either a single 1000 mg dose of intravenous FCM approximately 12 h before surgery or no iron supplementation. All the patients were managed with a standardized restrictive transfusion strategy. The primary outcome was all-cause mortality at 6 and 12 months. The secondary outcomes included perioperative transfusion requirement, hemoglobin trends, and length of hospital stay. Results: The FCM group demonstrated significantly lower mortality at both 6 months (22.9% vs. 39.0%, p = 0.011) and 12 months (28.4% vs. 42.9%, p = 0.028) compared to the control group. Multivariate logistic regression identified preoperative FCM administration as one of the independent protective factors for mortality. The FCM group had significantly lower transfusion rates (30.9% vs. 45.5%, p = 0.02). No significant difference was observed at the 6-week follow-up in terms of the higher discharge hemoglobin levels seen in the control group. The difference in hospital stay duration did not reach statistical significance. Conclusions: Preoperative intravenous FCM administration could reduce both short- and long-term mortality and transfusion needs in geriatric hip fracture patients managed under a restrictive transfusion protocol. These findings support further investigation of high dose IV iron as a component of perioperative blood management in this high-risk population.
- Open Access
- 9 June 2025
- Published by MDPI AG in Preprints.org
The Effect of Preoperative Intravenous Iron Supplementation on Mortality and Blood Transfusion Requirements in Elderly Patients Undergoing Hip Fracture Surgery: A Prospective Randomized Controlled Trial
Background/Objectives: Hip fractures in elderly patients are associated with high morbidity and mortality, often worsened by perioperative anemia. Although restric-tive transfusion strategies are recommended, the role of preoperative intravenous iron, particularly ferric carboxymaltose (FCM) remains unclear. This study aimed to investigate whether preoperative IV FCM reduces mortality and transfusion requirements in geriatric hip fracture patients managed under a restrictive transfusion strategy. Methods: In this prospective, randomized controlled trial, 220 patients aged ≥65 years undergoing surgery for hip fractures were allocated to receive either a single 1000 mg dose of intravenous FCM approximately 12 hours before surgery or no iron supplementation. All patients were managed with a standardized restrictive transfusion strategy. Primary outcome was all-cause mortality at 6 and 12 months. Secondary outcomes included perioperative transfusion requirement, hemoglobin trends, and length of hospital stay. Results: The FCM group demonstrated significantly lower mortality at both 6 months (22.9% vs. 39.0%, p = 0.011) and 12 months (28.4% vs. 42.9%, p = 0.028) compared to the control group. Multivariate logistic regression identified preoperative FCM administration as an independent protective factor for mortality. Transfusion rates (30.9% vs. 45.5%, p = 0.02) and transfusion index were significantly lower in the FCM group. Discharge hemoglobin levels were higher in the FCM group, although no significant difference was observed at 6-week follow-up. The difference in hospital stay duration did not reach statistical significance. Conclusions: Preoperative intravenous FCM administration could reduce both short- and long-term mortality and transfusion needs in geriatric hip fracture patients managed under a restrictive transfusion protocol. These findings support further investigation of FCM as a component of perioperative blood management in this high-risk population.
- 9 June 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Effect of Preoperative Intravenous Iron Supplementation on Mortality and Blood Transfusion Requirements in Elderly Patients Undergoing Hip Fracture Surgery: A Prospective Randomized Controlled Trial
Background/Objectives: Hip fractures in elderly patients are associated with high morbidity and mortality, often worsened by perioperative anemia. Although restric-tive transfusion strategies are recommended, the role of preoperative intravenous iron, particularly ferric carboxymaltose (FCM) remains unclear. This study aimed to investigate whether preoperative IV FCM reduces mortality and transfusion requirements in geriatric hip fracture patients managed under a restrictive transfusion strategy. Methods: In this prospective, randomized controlled trial, 220 patients aged ≥65 years undergoing surgery for hip fractures were allocated to receive either a single 1000 mg dose of intravenous FCM approximately 12 hours before surgery or no iron supplementation. All patients were managed with a standardized restrictive transfusion strategy. Primary outcome was all-cause mortality at 6 and 12 months. Secondary outcomes included perioperative transfusion requirement, hemoglobin trends, and length of hospital stay. Results: The FCM group demonstrated significantly lower mortality at both 6 months (22.9% vs. 39.0%, p = 0.011) and 12 months (28.4% vs. 42.9%, p = 0.028) compared to the control group. Multivariate logistic regression identified preoperative FCM administration as an independent protective factor for mortality. Transfusion rates (30.9% vs. 45.5%, p = 0.02) and transfusion index were significantly lower in the FCM group. Discharge hemoglobin levels were higher in the FCM group, although no significant difference was observed at 6-week follow-up. The difference in hospital stay duration did not reach statistical significance. Conclusions: Preoperative intravenous FCM administration could reduce both short- and long-term mortality and transfusion needs in geriatric hip fracture patients managed under a restrictive transfusion protocol. These findings support further investigation of FCM as a component of perioperative blood management in this high-risk population.